Publications Supporting Material
Keng, M.J., Leal, J., Bowman, L., Armitage, J., Mihaylova, B., on behalf of the ASCEND Study Collaborative Group (2022). Hospital costs associated with adverse events in people with diabetes in the UK. Diabetes Obes Metab. Accepted Author Manuscript. https://doi.org/10.1111/dom.14796. Download variance-covariance matrix.
Schlackow I, Simons C, Oke J, Feakins B, O'Callaghan CA, Hobbs FDR, et al. Long-term health outcomes of people with reduced kidney function in the UK: A modelling study using population health data. PLoS Med. 2020;17(12):e1003478. https://www.ncbi.nlm.nih.gov/pubmed/33326459. For the R code of the CKD-CVD policy model (License: MIT License) and the codelists to specify disease endpoints and patient characteristics using CPRD data please click HERE.
Keng MJ, Tsiachristas A, Leal J, Gray A, Mihaylova B. Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs. Diabetes Obes Metab. 2019;1–8. doi: 10.1111/dom.13821. Download accompanying Excel workbook. Link to publication: https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.13821
Price A., Smith J., Dakin H., Kang S., Eibich P., Cook J., et al. The Arthroplasty Candidacy Help Engine tool to select candidates for hip and knee replacement surgery: development and economic modelling. Health Technol Assess 2019;23(32) Price A, Smith J, Dakin H, Kang S, Eibich P, Cook J, et al. The Arthroplasty Candidacy Help Engine tool to select candidates for hip and knee replacement surgery: development and economic modelling. Health Technol Assess 2019;23(32) https://doi.org/10.3310/hta23320. Download variance-covariance matrices for mapping algorithms.
Schlackow I, Kent S, Herrington W, et al. A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart 2017;103(23):1880-90. https://heart.bmj.com/content/103/23/1880 For the R code of the SHARP CKD-CVD policy model (License: MIT License) please click HERE.
Kent S., Haynes R., Hopewell J.C., Parish S., Gray, A., Landray M.J., Collins R., Armitage, J., and Mihaylova B, on behalf of the HPS2-THRIVE Collaborative Group. The Effects of Vascular and Nonvascular Adverse Events and of Extended Release Niacin with Laropiprant on Health and Healthcare Costs, Circulation: Cardiovascular Quality and Outcome. EPub July 2016. Download cost and QoL calculator.
Kent S, Schlackow I, Lozano-Kühne J, Reith C, Emberson J, Haynes R, Gray A, Cass A, Baigent C, Landray MJ, Herrington W, Mihaylova B, on behalf of the HPS2-THRIVE Collaborative Group. 2015. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? BMC Nephrology, 16:65; DOI: 10.1186/s12882-015-0054-0 Download cost calculator here.
M.L. Alva , A. Gray, B. Mihaylova, J. Leal , R. R. Holman. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabetic Medicine. DOI: 10.1111/dme.12647.
For further information and to download the cost calculator please click here
Dakin HA, Welton NJ, Ades AE, Collins S, Orme M, Kelly S. Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open-angle glaucoma and ocular hypertension. Stat Med 2011; 30, 2511-35.
Dakin, H, Gray, A, Murray, D. (2013) Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Quality of Life Research. 22(3):683-94.
Campbell, HE, Gray, AM, Harris, AL, Briggs, AH, and Taylor, MA (2010). Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. Br J Cancer, 103(6):776-86.
Mihaylova, B, Briggs, A, O'Hagan, A, and Thompson, SG (2010). Review of statistical methods for analysing healthcare resources and costs. Health Economics, Epub 2010, 27 Aug.
Gray, A. M, Clarke, P. M, Wolstenholme, J. and Wordsworth, S. (2010) Applied Methods of Cost-effectiveness Analysis in Health Care. OUP.
Gray, A. (2009). Cost Effectiveness of Radon Control. In: World Health Organisatio Handbook On Indoor Radon, a Public Health Perspective. Ed by Hajo Zeeb and Ferid Shannoun.
Rivero-Arias, O, Ouellet, M, Gray, A, Wolstenholme, J, Rothwell, PM, and Luengo-Fernandez, R (2010). Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making, 30(3):341-54.
Wolstenholme, J, Rivero-Arias, O, Gray, A, Molyneux, AJ, Kerr, RSC, Yarnold, JA, and Sneade, M (2008). Treatment pathways, resource use, and costs of endovascular coiling versus surgical clipping after aSAH. Stroke, 39(1):111-9.
Simon, J, Gray, A, Clarke, P, Wade, A, Neil, A, and Farmer, A (2008). Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ, 336(7654):1177-80.
Gray, AM, Rivero-Arias, O, and Clarke, PM (2006). Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making, 26(1):18-29.
Clarke, P, Gray, A, Legood, R, Briggs, A, and Holman, R (2003). The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med, 20(6):442-50.